Pharma-major
Lupin has received approval for its Sulfamethoxazole and Trimethoprim Oral Suspension USP, 200 mg/40 mg per 5 mL, from the United States Food and Drug Administration (USFDA).
The approval is given to market a generic equivalent of Bactrim Oral Suspension, 200 mg/40 mg per 5 mL, of Sun Pharmaceutical Industries, Inc.
According to the regulatory filing, Sulfamethoxazole and Trimethoprim Oral Suspension USP, 200 mg/40 mg per 5 mL, is indicated for the treatment and prevention of a wide variety of bacterial infections (such as middle ear, urine, respiratory, and intestinal infections), and certain type of pneumonia (pneumocystis-type).
Lupin stated that Sulfamethoxazole and Trimethoprim Oral Suspension USP (RLD: Bactrim) had estimated annual sales of approximately USD 19 million in the U.S. (IQVIA MAT September 2020).
At around 11.23 am, Lupin was trading at Rs1009.35 per piece up Rs8.75 or 0.87% on Sensex. The stock has surged to an intraday high of Rs1025 per piece.